AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8384011
Drug: Pentamidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine (2 mg/kg every other day intramuscularly, for a total of seven injections)
Trial: 8384011
Drug: Pentamidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine (2 mg/kg every other day for a total of only four injections)
Trial: 8384011
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg orally, twice a day for 28 days)
Trial: 29505880
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 14 days
Trial: 29505880
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PCV, amoxicillin, doxycycline)
Trial: 24530993
Drug: Hexyl 5‐aminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 6.25mg/ml
Trial: 24530993
Drug: Hexyl 5‐aminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 50mg/ml
Trial: 22932169
Drug: BUD/FORM (160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FORM (160/4.5 µg/inhalation) + as-needed BUD/FORM (640/18 µg/d)
Trial: 22932169
Drug: SALM/FP (100/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SALM/FP (100/1000 µg/d) + as-needed terbutaline (0.4 mg/inhalation)
Trial: 12025234
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of receptor tyrosine kinases (RTK) and Ras
Trial: 12025234
Drug: Natural and
RxNorm normalized name: Natural and artifical flavoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural and synthetic compounds, monoclonal antibodies, and antisense oligonucleotides as inhibitors of signal transduction
Trial: 11773987
Drug: verapamil SR/trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil SR/trandolapril 180/2 mg (VT)
Trial: 11773987
Drug: enalapril/hydroclorothiazide 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril/hydroclorothiazide 20/12.5 mg (EH)
Trial: 9022869
Drug: Knowledge-and-skills-building workshop
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge-and-skills-building workshop for chemical dependency staff on treatment of nicotine dependence
Trial: 3782428
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC; 150 mg) for 5 days
Trial: 27277213
Drug: ART with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART with TB treatment
Trial: 27277213
Drug: TB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB treatment only
Trial: 18711188
Drug: PF-3512676 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-3512676 (0.2 mg/kg subcutaneously on days 8 and 15 of each 3-week cycle)
Trial: 12558709
Drug: Topical collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical collagen daily
Trial: 12558709
Drug: Topical hydrocolloid
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrocolloid twice weekly
Trial: 9869576
Drug: Double combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double combination of zidovudine (ZDV) plus didanosine (ddI)
Trial: 9869576
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of nevirapine (NVP) plus ZDV plus ddI
Trial: 9869576
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of NVP plus ZDV plus ddI
Trial: 1669595
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg loratadine once daily
Trial: 26375541
Drug: Fentanyl ITS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl ITS (40 mcg/activation)
Trial: 26375541
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA morphine (1 mg/dose)
Trial: 15177522
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg/d for 6 months
Trial: 15177522
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg/d for 6 months
Trial: 11589258
Drug: Tramadol/APAP (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/APAP (37.5 mg/325 mg)
Trial: 11589258
Drug: Codeine/APAP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine/APAP (30 mg/300 mg)
Trial: 11477815
Drug: Xianzhen Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xianzhen Tablet (XZT) treated group, 30 patients, 8 weeks treatment
Trial: 8608658
Drug: Concurrent ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent ACE inhibitor
Trial: 2756523
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Trial: 2756523
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Trial: 25979190
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied during the bone consolidation period following mandibular distraction osteogenesis.
Trial: 18272020
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine sulphate (p.o.)
Trial: 15055563
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 220 microg everyday for 21 days
Trial: 15055563
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP AQ), 200 microg everyday for 21 days
Trial: 9460590
Drug: Atenolol therapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol therapy for 6 months
Trial: 3456621
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PGE2/day/patient (5 mg every 4 hours, 4 times a day)
Trial: 3456621
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lactose/day/patient (placebo)
Trial: 23442835
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg, Esomeprazole 40 mg
Trial: 23442835
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg, Lansoprazole 30 mg
Trial: 19881393
Drug: Azithromycin 30
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 30 mg/kg
Trial: 19881393
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg
Trial: 19881393
Drug: Erythromycin 50
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 50 mg/kg for 5 days
Trial: 18948636
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1.8 g daily for 3 months
Trial: 17304477
Drug: Teletherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teletherapy combined with radioisotope therapy
Trial: 17304477
Drug: Radioisotope therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioisotope therapy
Trial: 17304477
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy and radioisotopes)
Trial: 11908358
Drug: Colgate Winterfresh
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Winterfresh Gel (0.243% sodium fluoride)
Trial: 8731383
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (100 micrograms/kg)
Trial: 3862020
Drug: Nonsteroidal anti‐inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti‐inflammatory agents
Trial: 3862020
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of corticosteroids and nonsteroidal anti‐inflammatory agents
Trial: 23508601
Drug: Intervention (point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (point-of-care education, coaching, medication intensification)
Trial: 16736000
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (1.2 mg day(‐1) for 12 weeks)
Trial: 8273956
Drug: NMB-assisted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMB-assisted oral intubation (succinylcholine 1.5 mg/kg IV)
Trial: 8273956
Drug: NMB-assisted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMB-assisted oral intubation
Trial: 30843497
Drug: Ma‐al‐Shaeer (MS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ma‐al‐Shaeer (MS) 15 g of dried MS powder twice daily for 14 days
Trial: 30843497
Drug: Fexofenadine (FX)
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine (FX) 60 mg twice daily for 14 days
Trial: 25495272
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (5-day dual therapy with pantoprazole plus amoxicillin, followed by 5-day triple therapy with pantoprazole plus clarithromycin and metronidazole)
Trial: 25495272
Drug: Reverse sequential
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reverse sequential therapy (5-day triple therapy with pantoprazole plus clarithromycin and metronidazole, followed by 5-day dual therapy with pantoprazole plus amoxicillin)
Trial: 25495272
Drug: Reverse sequential
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reverse sequential therapy
Trial: 17034446
Drug: Reimbursement for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reimbursement for smoking cessation treatment (SCT) for 6 months
Trial: 15321933
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration of 5 ng ml(‐1)
Trial: 15321933
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration of 10 ng ml(‐1)
Trial: 15321933
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration of 15 ng ml(‐1)
Trial: 3109574
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin
Trial: 19968833
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg/day
Trial: 2444307
Drug: Bromocriptine 5
RxNorm normalized name: bromocriptine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 5 mg/day
Trial: 19968833
Drug: Bromocriptine 10
RxNorm normalized name: bromocriptine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 10 mg/day
Trial: 19968833
Drug: Bromocriptine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (all doses)
Trial: 18441691
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment adherence
Trial: 18441691
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for missed drug intake
Trial: 18441691
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to regular drug intake
Trial: 9546995
Drug: Device therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device therapy in a blinded manner
Trial: 8391856
Drug: N-9 twice
RxNorm normalized name: (+/-)-N-methylephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-9 twice a day
Trial: 24080019
Drug: Drug naive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug naive controls
Trial: 15339055
Drug: Carboplatin/gemcitabine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/gemcitabine combination
Trial: 15339055
Drug: Carboplatin/gemcitabine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/gemcitabine combination (3-week schedule)
Trial: 8432481
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporin (4.1 mg/kg/day)
Trial: 2835836
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic preparation (neomycin, bacitracin, and polymyxin B)
Trial: 24201233
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) up to 2 g/d
Trial: 19370425
Drug: Proton-beam therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-beam therapy (PBT)
Trial: 19370425
Drug: 3D conformal
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D conformal X-ray therapy (3D-CRT)
Trial: 16674614
Drug: Nasopharyngeal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasopharyngeal oxygen insufflation at a flow of 5 l.min(‐1)
Trial: 14571613
Drug: Kangxin capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangxin capsule (KXC)
Trial: 11089449
Drug: Hydrocortisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (40 mg, p.o.)
Trial: 1456568
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy (controlled nutritional support)
Trial: 31337298
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with successful reperfusion
Trial: 24758079
Drug: Busheng Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busheng Huoxue Capsule (BHC) plus caltrate-D (600 mg CaCO3)
Trial: 24758079
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg per week) plus caltrate-D
Trial: 23106761
Drug: Modified Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Cognitive Processing Therapy (MCPT)
Trial: 20124230
Drug: Extended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended therapy (Nicoderm CQ, 21 mg, for 24 weeks)
Trial: 12542901
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefepime (4-g continuous infusion over 24 h for 48 h)
Trial: 12542901
Drug: Intermittent injection
RxNorm normalized name: Jelco Intermittent Injection Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent injection of cefepime (2-g bolus every 12 h for 48 h)
Trial: 8873689
Drug: Bumetanide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (single intravenous bolus dose, doses ranged from 0.005 to 0.100 mg/kg)
Trial: 8873689
Drug: Bumetanide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (single intravenous bolus dose)
Trial: 1300059
Drug: Urapidil 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 12.5 mg
Trial: 23642785
Drug: Monthly bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly bevacizumab
Trial: 31539373
Drug: Vignette portraying
RxNorm normalized name: Ultra Violette Mini Mates Duo Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vignette portraying effectively treated mental illness or treatment followed by subsequent relapse
Trial: 22415477
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks) with chemotherapy
Trial: 22415477
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (placebo)
Trial: 16303936
Drug: linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linoleic acid (LA; 112 mg) and gamma‐linolenic acid (GLA; 15 mg) administered twice daily for 1 month
Trial: 16303936
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 1 month
Trial: 11575865
Drug: Nimodipine 60
RxNorm normalized name: nimodipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 60 mg four times daily (240 mg/d)
Trial: 11575865
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg four times daily (120 mg/d)
Trial: 8349366
Drug: Heparin exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin exercise treatment (5000 IU intravenous dose, treadmill exercise 20 times for 2-3 weeks)
Trial: 3329125
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 2550 mg/day
Trial: 19810125
Drug: Adjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant concurrent chemoradiotherapy (CCRT)
Trial: 30293208
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (15 g prebiotics and 5 g probiotics containing Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum) for 12 weeks
Trial: 30293208
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (5 g probiotics and 15 g maltodextrin) for 12 weeks
Trial: 30293208
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g maltodextrin) for 12 weeks
Trial: 27487193
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate 18 mg (with potential increases up to 72 mg/d)
Trial: 15152897
Drug: zopiclone 5
RxNorm normalized name: zopiclone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zopiclone 5 mg
Trial: 25617762
Drug: zopiclone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zopiclone 10 mg
Trial: 25617762
Drug: alcohol 50
RxNorm normalized name: nicotinyl alcohol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcohol 50 g
Trial: 23896972
Drug: Bone-marrow derived
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow derived cell therapy (BMC) with a cell number above the median (324 × 10^6)
Trial: 23896972
Drug: Bone-marrow derived
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow derived cell therapy (BMC) with a cell number below the median
Trial: 23896972
Drug: Bone-marrow derived
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow derived cell therapy (BMC) without microvascular obstruction (MO)
Trial: 23896972
Drug: Bone-marrow derived
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow derived cell therapy (BMC)
Trial: 21521847
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (800 IU daily for 96 weeks)
Trial: 21521847
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg daily for 96 weeks)
Trial: 16977654
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 U once weekly for < or = 16 weeks)
Trial: 16977654
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (delayed treatment until hemoglobin < 9 g/dL)
Trial: 10917932
Drug: Procyanidin-rich chocolate
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procyanidin-rich chocolate (5.3 mg total procyanidin/g, 1.3 mg/g (‐)‐epicatechin)